For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    Biocon Rallies 5% On Novel Therapy Launch For Hepatitis C

    |

    Shares in Biocon surged 5.70 per cent after the company introduced an advanced novel therapy CIMIVIR-L for the treatment of Hepatitis C in India.

    The stock was last trading higher by 5.70 per cent on the NSE at Rs 567. "The introduction of CIMIVIR-L will strengthen Biocon's current portfolio of verilogy products," the company said in a release to the bourses.

    Biocon Rallies 5% On Novel Therapy Launch For Hepatitis C
    CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV).
     

    "It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities. CIMIVIR-L is indicated for Hepatitis-C Genotype 1 patients who account for ~25% of the total estimated HCV patient population of 18 million in the country," the company said in a release.

    GoodReturns.in

    Read more about: biocon
    Story first published: Thursday, December 24, 2015, 11:46 [IST]
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more